Bausch & Lomb Incorporated, Novartis AG, and Sun Pharmaceutical Industries Ltd Dominated the Global Ocular Pain Market in 2020

The Global Ocular Pain Market is expected to grow with a CAGR of 6.5% in the forecast period of 2021 to 2028. The years considered for the study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-ocular-pain-market

The global ocular pain market is a highly consolidated market, including a specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenarios.

The major players dealing in the global ocular pain market are introducing a strong range of product providers, launching new products, and adopting strategic initiatives such as acquisition, agreement, business expansion, award, and recognition. This helped companies to maximize sales with an enhanced product portfolio.

For instance,

  • In July 2021, Bausch & Lomb Incorporated announced on their website that they launched Biotrue Hydration Boost Lubricant Eye Drops and Biotrue Micellar Eyelid Cleansing Wipes. These products are preservative-free and provide the best therapeutic options for dry eyes. This thereby improved their revenue for the market

Bausch & Lomb Incorporated is the dominating player in the global ocular pain market. The other key players existing in the market are Johnson & Johnson Services, Inc., Pfizer Inc., EyePoint Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Akorn Operating Company LLC, AERIE PHARMACEUTICALS, INC., Sun Pharmaceutical Industries Ltd, Ocular Therapeutix, Inc., Kala Pharmaceuticals, Novartis AG, Omeros Corporation, Allergan (An AbbVie Company), SiteOne Therapeutics, Inc., Sylentis, Pharmaleads SA, Formosapharma Pharmaceutical Inc., Fera Pharmaceuticals, Vyluma, TALLC Inc., OKYO Pharma Limited, Novaliq GmbH, IACTA Pharmaceuticals, Inc., Allakos Inc., Aldeyra Therapeutics, Inc., Tarsier Pharma Ltd, among others.

Ocular Pain Market Bausch & Lomb Incorporated

Bausch & Lomb Incorporated headquarter is in Quebec, Canada, and was founded in 1853. It has public ownership. The company focuses on improving people's lives with health care products delivering on our commitments to patients, health care providers, other stakeholders, and society to advancing global health. The company has many business segments like Bausch +Lomb/ International, Salix, Ortho Dermatologic, and Diversified Products, where Bausch +Lomb/International segment is the market-focused segment. The company has several product categories, including Contact Lenses, Contact Lens Care, Dry Eye Products, Allergy/Redness Relief, Rx Pharmaceutical, Eye Wash, Eye Vitamins, Surgical Products, Vision Accessories, Safety, and Industrial Cleaning Products and Diagnostics in which Rx Pharmaceuticals is the market-focused category.

For instance,

  • In September 2020, Bausch & Lomb Incorporated announced on their website that the company successfully acquired options for purchasing all the ophthalmology assets of Allegro Ophthalmic, LLC, a private biopharmaceutical company working for ocular diseases. This acquisition helped the company in improving their revenue over the market

The company has a wide presence across North America, Europe, Asia-Pacific, Middle East, Africa, and South America. The company also has various subsidiary companies, including Bausch & Lomb Argentina S.R.L. (Argentina), Waicon Vision S.A. (Argentina), Bausch & Lomb (Australia), Pty Limited (Australia), Bausch Health Australia Pty Limited (Australia), Wirra Holdings Pty Limited (Australia), Bausch Health Closed Joint-Stock Company (Belarus), and Bausch & Lomb Pharma S.A. (Belgium) among others.

Novartis AG

Novartis AG was founded in the year 1996, headquartered in Basel, Switzerland. It has public ownership. The company focuses on innovating new solutions for various health care challenges. The company operates its business via two business segments, including Innovative Medicines, Sandoz, in which Innovative Medicines is the market-focused segment. The company has many product categories, including Cancer, Cardiovascular, Renal and Metabolism, Immunology and Dermatology, Ophthalmology, Neuroscience, and Respiratory, in which Ophthalmology is the market-focused category.

  • In September 2018, Novartis AG proudly announced that the company won the Ophthalmology Vision Award (XOVA) 2018 for non-profit eye health initiatives. The award for presented to the company at Euretina 2018. All the award winners were planning to help create sustainable eye clinics, train professionals, and improve awareness among the rural population. This helped company in gaining more global recognition

The company has a presence across the Americas, Asia-Pacific, Europe/Middle East /Africa. The company also has various subsidiaries, including Novartis Argentina S.A., Buenos Aires (Argentina), Novartis Australia Pty Ltd, Macquarie Park, NSW(Australia), Novartis Austria GmbH, Vienna (Austria), Novartis Pharma NV, Vilvoorde (Belgium), Sandoz (China) Pharmaceutical (China) among others.

Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd was founded in the year 1983, headquartered in New Jersey, U.S. It has public ownership. The company mainly works in the area of pharmaceutical products. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients. The company operates in three business segments, including US business, Indian branded generics business, and emerging markets in which US business is the market-focused segment. The company has many product categories, which are Specialty Medications, Generic Medications, Over-the-Counter Medications, Active Pharmaceutical Ingredients, and Anti-Retro Viral Medications. Generic Medications is the market-focused product category.

  • In November 2018, Sun Pharmaceutical Industries Ltd entered into a definitive agreement to acquire Pola Pharma Inc. The acquired company is a Japanese pharmaceutical company engaged in research and development, manufacture, sale, and distribution of branded and generic products in Japan. This acquisition has enhanced the company’s footprints in Japan and leading to increased demand and sales of products in future

The company has a presence across North America, South America, Europe, Asia-Pacific, Middle East, and Africa. The company also has various subsidiaries, including Independence Way LLC (USA), Skyline LLC (USA), Aditya Acquisition Company Ltd. (Israel), Alkaloida, Chemical Company Zrt. (Hungary), AO Ranbaxy (Russia), Basics GmbH (Germany).